CO2020004359A2 - Composicion farmaceutica que comprende tetrofosmina y sales farmaceuticamente aceptables del mismo - Google Patents

Composicion farmaceutica que comprende tetrofosmina y sales farmaceuticamente aceptables del mismo

Info

Publication number
CO2020004359A2
CO2020004359A2 CONC2020/0004359A CO2020004359A CO2020004359A2 CO 2020004359 A2 CO2020004359 A2 CO 2020004359A2 CO 2020004359 A CO2020004359 A CO 2020004359A CO 2020004359 A2 CO2020004359 A2 CO 2020004359A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
acceptable salts
pharmaceutical composition
tetraphosmin
tetraphosmine
Prior art date
Application number
CONC2020/0004359A
Other languages
English (en)
Inventor
Umamaheshwar M Prasad
Harmik Sohi
Rahul Hasija
Dinesh Kumar
Kamal S Mehta
K Vijaya Raj K
Ashutosh Agarwal
Dharam Vir
Original Assignee
Jubilant Generics Ltd Formerly A Division Of Jubilant Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Generics Ltd Formerly A Division Of Jubilant Life Sciences Ltd filed Critical Jubilant Generics Ltd Formerly A Division Of Jubilant Life Sciences Ltd
Publication of CO2020004359A2 publication Critical patent/CO2020004359A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5027—Polyphosphines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN La presente invención se relaciona con una composición farmacéutica estable de tetrofosmina o sales farmacéuticamente aceptables de la misma. También se relaciona con un kit no radioactivo liofilizado el cual con reconstitución con solución de 99mTc-pertecnetato da una composición radiofarmacéutica estable de 99mTc-tetrofosmina. También se suministra el proceso para la preparación de dichas composiciones radiofarmacéuticas y su uso en procedimientos de imágenes de diagnóstico. Las composiciones suministran atributos técnicos deseables tales como estabilidad, alta pureza radioquímica (RCP) y bio distribución deseada.
CONC2020/0004359A 2017-11-23 2020-04-13 Composicion farmaceutica que comprende tetrofosmina y sales farmaceuticamente aceptables del mismo CO2020004359A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711042108 2017-11-23
PCT/IB2018/059209 WO2019102388A1 (en) 2017-11-23 2018-11-22 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
CO2020004359A2 true CO2020004359A2 (es) 2020-04-24

Family

ID=66631399

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004359A CO2020004359A2 (es) 2017-11-23 2020-04-13 Composicion farmaceutica que comprende tetrofosmina y sales farmaceuticamente aceptables del mismo

Country Status (9)

Country Link
US (2) US11857647B2 (es)
EP (1) EP3661486A4 (es)
JP (1) JP2021504296A (es)
CN (1) CN111050751A (es)
AU (1) AU2018372768B2 (es)
BR (1) BR112020005243A2 (es)
CA (1) CA3075958C (es)
CO (1) CO2020004359A2 (es)
WO (1) WO2019102388A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233284A (en) * 1978-03-31 1980-11-11 The Procter & Gamble Company Stabilized radiographic scanning agents
EP0078642B1 (en) * 1981-10-30 1986-12-10 AMERSHAM INTERNATIONAL plc Radiopharmaceutical composition based on technetium-99m and reagent for making it
CN1184225C (zh) * 2000-06-28 2005-01-12 北京师范大学 一种替曲膦季鏻盐及其制法和二步法替曲膦药盒及其应用
GB0031592D0 (en) 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
EP2899195A1 (en) * 2014-01-28 2015-07-29 ROTOP Pharmaka AG Stabilized form of Tetrofosmin and its use

Also Published As

Publication number Publication date
CA3075958C (en) 2022-04-19
CA3075958A1 (en) 2019-05-31
JP2021504296A (ja) 2021-02-15
US20210145987A1 (en) 2021-05-20
BR112020005243A2 (pt) 2020-09-24
AU2018372768A1 (en) 2020-04-02
AU2018372768B2 (en) 2021-07-01
EP3661486A4 (en) 2020-12-02
US11857647B2 (en) 2024-01-02
US20240050598A1 (en) 2024-02-15
CN111050751A (zh) 2020-04-21
WO2019102388A1 (en) 2019-05-31
EP3661486A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
CL2008003480A1 (es) Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
BR112017018643A2 (pt) "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas"
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
BR112021006598A2 (pt) composição farmacêutica líquida, e, kit
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX2018011696A (es) Composición farmacéutica de dapagliflozina.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
CO2020004359A2 (es) Composicion farmaceutica que comprende tetrofosmina y sales farmaceuticamente aceptables del mismo
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
TR201902755T4 (tr) Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos